https://www.mountsinai.org/care/dermatology

Mount Sinai Dermatology, Harlem, NY (2025)

07/17/2025

Congratulations! We are grateful for Tomlee L. Abraham, celebrating 20 years with Mount Sinai. 👏 🙌 His commitment to excellence is truly inspiring, and we deeply appreciate the leadership that empowers our team to achieve new heights every day. The Mount Sinai Hospital Icahn School of Medicine at Mount Sinai

07/16/2025

We are ranked #6 in Research Output &
#11 in Overall Reputation in the US 🇺🇸 on Residency Navigator 🎉🙌👏
See the ranking: https://www.doximity.com/residency/
from the largest survey and CV analysis of current residents & recent alumni
Icahn School of Medicine at Mount Sinai The Mount Sinai Hospital

07/14/2025

Summer is the season for being outside. ☀️ 🌞 Our expert, Dr. Jonthan Ungar, explained the strong link between sun exposure and skin cancer, and what we can do to protect ourselves.

Dr. Jonathan Ungar took questions from listeners about sunscreen: mineral vs. chemical, SFP, sunscreen in makeup, expiration dates and more, on a recent episode of Science Friday. Details: http://bit.ly/44sPfxK Icahn School of Medicine at Mount Sinai The Mount Sinai Hospital

07/14/2025

Many treatment guidelines for psoriasis rely heavily on body surface area (BSA) involvement to determine disease severity and eligibility for systemic therapies like biologics. Traditionally, patients with less than 10% BSA involvement—especially those under 3%—have faced barriers to accessing biologics, despite experiencing substantial disease burden. This study written in part by Dr. Khattri and her esteemed colleagues from the CorEvitas Psoriasis Registry explored whether patients with low BSA involvement initiating biologic therapy report comparable disease impacts to those with higher BSA involvement.

📚https://bit.ly/4lfTQJc

Analyzing data from over 1,600 biologic-naïve patients starting systemic therapy, this study stratified participants into low (10%) BSA groups. Surprisingly, patient-reported outcomes (PROs)—including quality of life, itch, pain, and fatigue—showed considerable overlap across all BSA categories. In fact, patients with low BSA had similar or even greater disease burden compared to those with more extensive skin involvement, particularly when psoriasis affected high-impact sites like the scalp, nails, palms, and soles. Notably, nearly half of the patients with low BSA had psoriasis in these difficult-to-treat areas, and over 40% screened positive for psoriatic arthritis.

These findings challenge the traditional reliance on BSA thresholds alone to guide treatment decisions and underscore the importance of evaluating the total disease impact, including high-impact anatomical sites and patient-reported quality of life. Clinicians should feel empowered to advocate for systemic therapies, including biologics, in patients with low BSA when disease burden is high.

This study reinforces the evolving perspective that psoriasis severity cannot be fully captured by surface area alone. Recognizing the complex, individualized burden of disease is essential for ensuring that all patients have access to appropriate treatment options.

Icahn School of Medicine at Mount Sinai
The Mount Sinai Hospital

07/11/2025

Nail lichen planus (NLP) is a rare but severe inflammatory condition that can lead to irreversible nail damage if not treated early. In this JAAD Case Report, Dr. Eric Loesch from Mount Sinai and colleagues present a striking case of NLP triggered by imatinib mesylate, a tyrosine kinase inhibitor used in chronic myeloid leukemia. The patient developed mucocutaneous lichenoid eruptions and progressive nail dystrophy shortly after starting imatinib, which continued even after the drug was discontinued. Physical findings included pterygium, nail atrophy, and severe fragility—hallmarks of advanced NLP. 💅🧬⚠️

📚https://shorturl.at/dkOPa

This case underscores the need for dermatologists to recognize NLP as a potential adverse effect of imatinib. Although cutaneous lichenoid reactions are rare, NLP is even more uncommon and often overlooked—yet it can have a profound impact on patient function and quality of life. Once scarring sets in, nail loss may be permanent. Timely intervention is crucial. Intralesional steroids remain first-line therapy, but may be less effective once damage has progressed, as seen in this patient. Emerging treatments like JAK inhibitors show promise but lack FDA approval for this indication. 💉🔍📉

As oncology patients live longer on targeted therapies, vigilance for delayed dermatologic toxicities is more important than ever. Collaboration between dermatology and oncology teams is essential to manage these complex cases and prevent irreversible outcomes. 👩‍⚕️🧪🧠

Icahn School of Medicine at Mount Sinai The Mount Sinai Hospital

07/10/2025

We Celebrate and Elevate— Gabriella Rodriguez, Medical Office Specialist, Dermatology! 👏 🙌
Please join us in celebrating Gabriella for her teamwork. She learns quickly, takes feedback with ease, and is truly one of the great team players. Patients describe her as “friendly and very kind”. Thank you for going above and beyond to support the team and create a welcoming experience for our patients.
The Mount Sinai Hospital

07/10/2025

In a new analysis of the phase 3 POETYK PSO-1 and PSO-2 trials by Dr. Lebwohl from Icahn School of Medicine at Mount Sinai and colleagues from other esteemed institutions, deucravacitinib—a once-daily oral selective TYK2 inhibitor—showed significantly greater efficacy than placebo in patients with moderate to severe plaque psoriasis. Patients treated with deucravacitinib achieved rapid improvements in PASI scores as early as Week 1, with sustained responses through Week 52. These included clinically meaningful reductions in overall PASI, as well as superior outcomes across individual body regions (head, trunk, limbs) and plaque features (erythema, induration, desquamation). High proportions of patients reached absolute PASI thresholds (≤1 to ≤5), reinforcing its potential as a treat-to-target therapy in routine clinical practice. ✨📊💊

📚https://shorturl.at/JfpOP

Why this matters: Treat-to-target strategies using absolute PASI scores are increasingly recognized for aligning better with patient-centered outcomes than relative improvements like PASI 75. Deucravacitinib’s strong and consistent efficacy across affected regions—including the visibly impactful head and neck—supports its role in improving both disease severity and quality of life. As an oral agent, it offers a convenient alternative to injectable biologics, helping expand access and adherence for patients managing chronic psoriasis. 🌍🧴📈🧬

The Mount Sinai Hospital

07/09/2025

The nervous and immune systems are more intertwined than previously imagined. This perspective by Dr. Brian Kim and Dr. David Artis explores the rapidly growing field of sensory neuroimmunology, revealing how neurons and immune cells co-regulate inflammation, tissue repair, allergy, infection, and even cancer. 🧠🧬🔥 From itch-inducing cytokines to microbe-sensing neurons, the skin—and other barrier tissues—are proving to be dynamic neuroimmune interfaces with broad implications for health and disease.

📚https://shorturl.at/3DsKA

IL-31, TSLP, and IL-33 directly activate sensory neurons to trigger itch, explaining the success of biologics like nemolizumab and dupilumab in atopic and chronic pruritic conditions. Even more striking: sensory neurons not only sense cytokines but also release neuropeptides (e.g., CGRP, substance P) that shape immune cell behavior, influence wound healing, and modulate inflammation across tissues. 🧪🩹

Environmental stimuli such as allergens, bacteria (e.g., S. aureus), and fungi (e.g., Candida) can directly activate nociceptors, promoting either protective or pathologic immune responses. In cancer, sensory neurons and their signals—like CGRP and substance P—may facilitate tumor growth, metastasis, or immune evasion. 🧫💥

Finally, vagal sensory neurons encode systemic inflammatory cues and trigger neuroimmune reflexes, offering promising targets for neuromodulatory therapies in autoimmunity and beyond. The future lies in decoding these neural-immune circuits, combining cutting-edge tools from neuroscience and immunology. 🌐🔬💡

Icahn School of Medicine at Mount Sinai The Mount Sinai Hospital

07/09/2025

Dr. Jonathan Ungar, Medical Director of the Kimberly and Eric J. Waldman Melanoma and Skin Cancer Center at Mount Sinai, showed CBS New York the Vectra WB180 system.
This new technology uses 3D total body photography and takes just seconds to capture concerning spots. Patient Jackie Mills, a 32-year-old public school teacher and melanoma survivor, has her moles monitored yearly by Dr. Ungar.
See the video: https://bit.ly/46Eayh4

Icahn School of Medicine at Mount Sinai
The Mount Sinai Hospital

07/08/2025

Dr. Emma Guttman commented on positive 16-week data from Part A of the Phase 2 APEX clinical trial of APG777, a potential best-in-class anti-IL-13 antibody, in patients with moderate-to-severe atopic dermatitis (AD). 🔬
“The Phase 2 Part A results are exciting, with APG777 demonstrating promising efficacy results from only four injection days over the initial 16-week induction period,” said Dr. Guttman. 💉 Details: https://bit.ly/APG777_Phase2_CT
APG777 could substantially decrease induction injections for patients (~50% fewer injections and dosing days) and showed rapid onset of itch relief (Week1) and lesion reduction (Week 2). Icahn School of Medicine at Mount Sinai

07/07/2025

We are proud to announce a transformative $5 million gift from Clifford S. Asness, PhD, and Laurel Asness to rename our Center of Excellence in Eczema to the Asness Family Center of Excellence in Eczema and Allergic Conditions, housed within the Kimberly and Eric J. Waldman Department of Dermatology. Details: https://bit.ly/AsnessFamilyCenter_Eczema
This gift will support the recruitment of a multidisciplinary research and clinical team, and accelerate the development of new therapies for patients with eczema and other associated allergic diseases such as asthma. Dr. Emma Guttman will serve as Director of the Asness Family Center. The Mount Sinai Hospital Icahn School of Medicine at Mount Sinai

07/03/2025

Biologics are a cornerstone of psoriasis care 🧬—but in a subset of patients, they may trigger paradoxical eczematous reactions (ERs). This collaborative study by Dr. Emma Guttman-Yassky, Dr. Mark Lebwohl, and colleagues at Icahn School of Medicine at Mount Sinai explores management strategies for these challenging cases. 🔍💡

📚https://shorturl.at/Tju5h

In this single-center retrospective review of 35 patients who developed ERs while on IL-17 or IL-23 inhibitors, researchers evaluated how switching or continuing biologic therapy influenced outcomes. Nearly 55% of patients had a history of atopy, a known risk factor for ERs. Discontinuing the psoriasis biologic occurred in over half of cases. Among those, switching to the JAK inhibitor upadacitinib (UPA) or continuing the psoriasis biologic with the addition of dupilumab led to the highest rates of complete resolution—100% and 85.7%, respectively. ✨🧴

Interestingly, switching to another psoriasis biologic alone was rarely effective, possibly due to class redundancy (e.g., switching within IL-17 or IL-23 agents). Meanwhile, combining topicals with the existing biologic showed moderate efficacy, but not as much as dupilumab or UPA, both of which target the Th2 axis. This supports the theory that ERs may arise from immune pathway shifting—blocking Th17 may upregulate Th2-driven inflammation. 🔁🔥

This study provides real-world guidance for navigating ERs, a growing challenge as biologic use increases. More importantly, it highlights the need for personalized treatment strategies rooted in immunologic mechanisms. 🌐🧠

The Mount Sinai Hospital

Mount Sinai Dermatology

07/17/2025

07/16/2025

07/14/2025

07/14/2025

07/11/2025

07/10/2025

07/10/2025

07/09/2025

07/09/2025

07/08/2025

07/07/2025

07/03/2025

Address

Website

Alerts

Contact The Practice

Shortcuts

Share

Category